Avastin meets second-line breast cancer endpoint

Genentech Inc. said Avastin bevacizumab plus chemotherapy met the primary endpoint of significantly increased progression-free survival (PFS) vs. chemotherapy alone in the Phase III RIBBON-2 trial to treat second-line HER2-negative metastatic breast cancer. The double-blind, international trial enrolled 684 patients. ...